+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating BLU-5937, an oral drug, in adults with refractory chronic cough, including unexplained chronic cough, in a randomized, double-blind, placebo-controlled Phase 3 study. The main goal is to assess how BLU-5937 affects 24-hour cough frequency over 24 weeks. This study also monitors safety by tracking adverse events and changes in various health parameters during the treatment period. Participants are randomly assigned to one of three groups BLU-5937 25 mg twice daily, BLU-5937 50 mg twice daily, or a matching placebo taken twice daily. The treatment lasts for 24 weeks, and participants receive their assigned oral medication regularly throughout this time. The study uses a parallel-arm design and includes an extension in China. During the study, participants undergo assessments including cough frequency measurement, vital signs, blood tests for hormones and chemistry, hematology, and ECGs at baseline and Week 24. Researchers also evaluate cough severity and quality of life using questionnaires. Safety is closely monitored by recording adverse events, treatment discontinuations, and laboratory changes. The total participation duration is 24 weeks, with follow-up assessments at specified intervals.

Age: 18Years - 80YearsAll GendersPhase 3
38 locations
P

Actively Recruiting

Researchers are evaluating TQB2102, an antibody-drug conjugate designed to target Human Epidermal Growth Factor Receptor 2 HER2 in patients with locally advanced or metastatic non-small cell lung cancer who have HER2 gene abnormalities. This Phase 2 study aims to assess the effectiveness and safety of TQB2102, which combines targeted antibody action with a potent drug payload that is normally too toxic for general use. Participants receive TQB2102 through intravenous infusion every three weeks, with each treatment cycle lasting 21 days. Some participants will receive TQB2102 alone, while others will receive TQB2102 combined with Benmelstobart, another intravenous drug targeting programmed death ligand-1 PD-L1. Both treatments are given over multiple cycles to evaluate their effects. During the study, participants will be closely monitored through various assessments including measuring tumor response over up to eight months, tracking survival, and recording any adverse events from the start of treatment until 28 days after the last dose. Researchers will also check for immune responses to the drug at several points during and after treatment. The total participation may last up to 18 months to gather comprehensive safety and effectiveness data.

Age: 18Years - 75YearsAll GendersPhase 2
25 locations
P

Actively Recruiting

This research aims to evaluate the safety and effectiveness of TQA2225AP025, a recombinant human FGF21-Fc fusion protein, in adults with Non-Alcoholic Steatohepatitis NASH. It is a randomized, double-blind, placebo-controlled Phase II study designed to assess how well two different doses of this treatment work in managing NASH, a liver condition characterized by fat buildup and inflammation. Participants will receive either 25mg or 50mg of TQA2225AP025 or a matching placebo, given by weekly subcutaneous injections for 48 weeks. The study includes two experimental groups receiving the different doses, and all treatments are administered under blinded conditions to assess the treatment effects accurately. During the study, participants will undergo liver biopsies at the start and after 48 weeks to measure changes in liver condition using the NASH CRN scoring system. Safety will be closely monitored by tracking any adverse events throughout the treatment period. The study is expected to provide detailed information on both the treatment impact on liver health and its safety profile over nearly a year of participation.

Age: 18Years - 75YearsAll GendersPhase 2
53 locations
E

Actively Recruiting

Researchers are evaluating the potential for Tezepelumab to help patients with severe asthma reduce their background maintenance medications while maintaining control of their asthma symptoms. This Phase 3b, single-arm study involves about 400 Chinese patients with severe asthma who are currently on medium to high doses of inhaled corticosteroids and long-acting beta-agonists, with or without additional controllers. The study aims to assess the safety and effectiveness of stepping down therapy after starting Tezepelumab. Participants will receive Tezepelumab treatment while their current asthma controller medications are gradually reduced under medical supervision. The study lasts up to 52 weeks and is conducted at approximately 70 sites in China. Patients continue on medium-high dose ICS-LABA with up to one additional controller at enrollment, and the study evaluates how well asthma control is maintained during and after the medication reduction. Throughout the study, participants will attend regular visits for assessments of lung function, asthma symptom control using questionnaires like the Asthma Control Questionnaire-5 and St. Georges Respiratory Questionnaire, and biomarkers related to severe asthma. Researchers will also monitor asthma exacerbations, nasal symptoms for those with comorbid nasal polyps, and daily symptoms through diaries. Safety and treatment adherence are closely tracked over the year-long study period.

Age: 12Years - 80YearsAll GendersPhase 3
75 locations